Hot Stocks: Brokerage view on Gland Pharma, Aditya Birla Fashion and PDS

Brokerage firm Morgan Stanley maintained an overweight rating on Gland Pharma, HDFC Securities initiated coverage on PDS and ICICIdirect has a buy on Aditya Birla Fashion.

We have collated a list of recommendations from top brokerage firms from ET NOW and other sources:

Morgan Stanley on Gland Pharma: Overweight| Target Rs 2558
Morgan Stanley maintained an overweight stance on Gland Pharma with a target price of Rs 2558. Gland Pharma’s Chinese owner, Fosun Pharma, plans to sell the drugmaker. Read More

The proposed deal will be funded using net cash on Gland's balance sheet.

The deal appears complementary to Gland in terms of EU market access, branded pharma customer base and some technologies, the brokerage said. “We see the scope of meaningful value unlocking, subject to synergy execution,” said the note.

ICICIdirect on Aditya Birla Fashion & Retail: Buy| Target Rs 380
ICICIdirect maintained a buy rating on Aditya Birla Fashion & Retail with a target price of Rs 380.

Multiple strategic initiatives like entry into footwear by acquiring Reebok’s India operations, acquisition of a majority stake in Masaba to foray into the beauty category, the launch of premium menswear ethnic brand Tasva and setting up a separate platform to build a portfolio of D2C brands to add value over the medium to long-term," said ICICIdirect.

HDFC Securities on PDS: Buy| Target Rs 383
HDFC Securities initiated coverage on PDS with a buy rating and a target price of Rs 383. PDS (PDSL) is a design-led plug-and-play platform, that provides customized manufacturing and sourcing solutions to the world's leading textile retailers and brands.

PDSL has the ambition to cross the $2.5 bn (~doubling from current levels) top-line mark over the next five years, powered by geographic expansion, operational excellence, strategic investments, collaborative partnerships, and a high-margin, asset-light business model, the brokerage said.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)